Pfizer On Track To Settle Rapamune Investigation; Protonix Probe Still Unresolved
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer has reached an agreement-in-principle with the Department of Justice in the Rapamune investigation and taken a charge of $491 million; Novartis settles allegations over the marketing of Elidel for $19.9 million.
You may also be interested in...
Wyeth Rapamune Off-Label Marketing Settlement Will Not Alter Pfizer’s CIA
Pfizer subsidiary to pay $490.9 million to resolve criminal and civil liability for marketing its immunosuppressive for unapproved uses; actions predate Pfizer’s 2009 corporate integrity agreement.
Pfizer Settles Protonix Off-Label Allegations – Pricing Investigation Still Unresolved
Pfizer finalizes a $55 million settlement with the Department of Justice concerning Wyeth’s Protonix promotional practices; a separate probe of alleged bundling of Protonix sales to hospitals continues.
Pfizer Settles Foreign Bribery Charges, Wins Deferred Prosecution For Helping Government
Pfizer reaches separate settlements with DoJ and SEC to resolve charges its subsidiaries bribed foreign government officials; a subsidiary enters a deferred prosecution agreement with DoJ.